Clinical Trial: A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07896005) titled 'A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer' on Oct. 19.

Brief Summary: This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer

Intervention: DRUG: SHR-A181...